Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring.Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives.

1958: A pivotal moment in Edwards’s career occurred in the late spring of 1958, when the 60 year old Edwards introduced himself to a 32-year-old cardiac surgeon, Albert Starr.

1963: In 1963, Starr and Edwards reported their clinical experience with aortic valve replacement with what they termed their “semi-rigid ball-valve prosthesis.” Aortic Replacement: Clinical Experience with a Semirigid Ball-Valve Prosthesis.

1966: In 1966, Edwards Laboratories was purchased by American Hospital Supply Corporation and became American Edwards Laboratories.

1985: Edwards was acquired by Baxter in 1985.

2000: In early 2000, the company was spun-off as an independent, publicly-held corporation and began trading on the New York Stock Exchange under the symbol “EW.”

2013: Harpoon, founded in 2013, developed a minimally invasive heart surgery product for mitral valve repair to treat degenerative mitral regurgitation.

2017: On January 25, 2017, Edwards completed the acquisition of Valtech Cardio for $340 million.

2019: On April 18, 2019, Edwards completed the acquisition of CAS Medical Systems of Branford, Connecticut for ~$100 million. Edwards SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valve systems were FDA-approved for the treatment of patients at low risk for death or major complications associated with open-heart surgery on August 16, 2019.

In edwards lifesciences and mission statement to, you must never develop transcatheter valve.